Since January 2000, Thorne Research has had the unique distinction of being inspected and approved by Australia's Therapeutic Goods Administration (TGA), the pharmaceutical regulatory agency of Australia. Considered the toughest regulatory agency in the world, the TGA inspection and certification is conducted at a pharmaceutical level standard. Only a handful of U.S. companies are able to achieve the status of holding a TGA certification. Thorne is unique in that it is the only U.S.-based manufacturer, serving the professional practitioner market, which has TGA approval for its U.S. manufacturing plant. Click here
to view certificate.
The auditors from this official agency of the Australian government, whose certification is recognized and accepted by other governments worldwide, not only review our GMPs every two years, but also conduct an on-site inspection of every aspect of Thorne's manufacturing and quality control. The TGA certification achieved by Thorne Research – for "medicinal products" – is the same certification that is designated for Australian pharmaceutical manufacturers, thus permitting Thorne, were it our business, to market pharmaceutical products in Australia and other countries that accept the TGA certification.
In September 2009, Thorne was again successfully audited by the TGA at its 58,000 sq. ft. facility in Dover, Idaho. TGA auditors always comment on the high standards that Thorne displays, not only in manufacturing, but also in quality control, laboratory procedures, pharmaceutical good manufacturing practices, and standard operating procedures.
The Thorne commitment to quality is demonstrated by the diligence necessary to maintain the level of pharmaceutical standards required by the TGA. Quality is the Thorne Vet mission, more than just a mission statement.